Patents by Inventor Kenneth J. Mandell

Kenneth J. Mandell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Toxic aldehyde related diseases and treatment
    Patent number: 10543181
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 28, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Dry eye treatments
    Patent number: 10456396
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: October 29, 2019
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20190247334
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: February 15, 2019
    Publication date: August 15, 2019
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20190231715
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: January 30, 2019
    Publication date: August 1, 2019
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • METHODS OF TREATING OCULAR CONDITIONS
    Publication number: 20190201397
    Abstract: Described herein are methods and pharmaceutical formulations for treating ocular conditions.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 4, 2019
    Applicant: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael ACKERMANN, James LOUDIN, Kenneth J. MANDELL
  • Toxic aldehyde related diseases and treatment
    Patent number: 10213395
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: February 26, 2019
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury
    Publication number: 20180271914
    Abstract: The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light.
    Type: Application
    Filed: March 21, 2017
    Publication date: September 27, 2018
    Applicant: Noveome Biotherapeutics, Inc.
    Inventors: David L. Steed, Kenneth J. Mandell
  • Dry Eye Treatments
    Publication number: 20170239244
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 24, 2017
    Applicant: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, JR., James Loudin, Kenneth J. Mandell
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20170239196
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 24, 2017
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Toxic aldehyde related diseases and treatment
    Patent number: 9687481
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: June 27, 2017
    Assignee: ALDEYRA THERAPEUTICS, INC.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Dry eye treatments
    Patent number: 9597284
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: March 21, 2017
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Methods of improving ocular discomfort
    Patent number: 9532944
    Abstract: Described herein are methods and pharmaceutical formulations for improving ocular discomfort.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: January 3, 2017
    Assignee: OYSTER POINT PHARMA, INC.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Methods of increasing tear production
    Patent number: 9504644
    Abstract: Described herein are methods and pharmaceutical formulations for increasing tear production.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: November 29, 2016
    Assignee: OYSTER POINT PHARMA, INC.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Pharmaceutical formulations for treating ocular conditions
    Patent number: 9504645
    Abstract: Described herein are pharmaceutical formulations for treating ocular conditions.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: November 29, 2016
    Assignee: OYSTER POINT PHARMA, INC.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • DRY EYE TREATMENTS
    Publication number: 20160106745
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: October 19, 2015
    Publication date: April 21, 2016
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • METHODS OF INCREASING TEAR PRODUCTION
    Publication number: 20160106744
    Abstract: Described herein are methods and pharmaceutical formulations for increasing tear production.
    Type: Application
    Filed: October 19, 2015
    Publication date: April 21, 2016
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • PHARMACEUTICAL FORMULATIONS FOR TREATING OCULAR CONDITIONS
    Publication number: 20160106746
    Abstract: Described herein are pharmaceutical formulations for treating ocular conditions.
    Type: Application
    Filed: October 19, 2015
    Publication date: April 21, 2016
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • OCULAR DISCOMFORT
    Publication number: 20160106665
    Abstract: Described herein are methods and pharmaceutical formulations for improving ocular discomfort.
    Type: Application
    Filed: October 19, 2015
    Publication date: April 21, 2016
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20150335632
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: January 23, 2014
    Publication date: November 26, 2015
    Inventors: Todd BRADY, Scott YOUNG, William A. KINNEY, Kenneth J. MANDELL
  • DRUG DELIVERY COATING AND DEVICES
    Publication number: 20130273137
    Abstract: In various embodiments, the present invention provides certain systems comprising a multi-layer decomposable film coating composition on a substrate, where the coating composition includes one or more releasable agents in at least one of its layers, and decomposes layer-by-layer to release such agent(s) over time. In some embodiments, an intra-ocular lens (IOL) system comprising an IOL coated with a multi-layer decomposable film coating composition is disclosed.
    Type: Application
    Filed: May 3, 2011
    Publication date: October 17, 2013
    Applicants: MASSACHUSETTS EYE & EAR INFIRMARY, Massachusetts Institute of Technology
    Inventors: Kenneth J. Mandell, Paula T. Hammond, Renee C. Fuller, Joseph F. Rizzo, III, Anita Shukla